Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
BRICANYL is an oral small-molecule tablet approved in 1975 by Sanofi for an undisclosed indication. The specific mechanism of action and therapeutic class are not publicly documented in available data, limiting clinical context.
Product is approaching loss of exclusivity with moderate competitive pressure (30), suggesting a contracting team and focus on generic transition planning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3
Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients
Zero linked job openings reflect the product's mature, pre-LOE stage with a stable but no-growth team. Career opportunities are limited to transition management, generic strategy, and potential cost optimization roles.
Worked on BRICANYL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.